Annick BÃ³rquez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5283593/publications.pdf Version: 2024-02-01



ANNICK RÃ3DOLIEZ

#	Article	IF	CITATIONS
1	HIV risk and preventive interventions in transgender women sex workers. Lancet, The, 2015, 385, 274-286.	13.7	297
2	Responding to global stimulant use: challenges and opportunities. Lancet, The, 2019, 394, 1652-1667.	13.7	169
3	The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. PLoS Medicine, 2012, 9, e1001323.	8.4	76
4	Understanding the modes of tranmission model of new HIV infection and its use in prevention planning. Bulletin of the World Health Organization, 2012, 90, 831-838.	3.3	56
5	Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. The Lancet Global Health, 2014, 2, e35-e43.	6.3	44
6	Peru's HIV care continuum among men who have sex with men and transgender women: opportunities to optimize treatment and prevention. International Journal of STD and AIDS, 2016, 27, 1039-1048.	1.1	42
7	Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. Journal of Theoretical Biology, 2019, 481, 194-201.	1.7	38
8	Implementation of preâ€exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. Journal of the International AIDS Society, 2016, 19, 21108.	3.0	34
9	The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. Lancet Public Health, The, 2018, 3, e429-e437.	10.0	33
10	Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV,the, 2018, 5, e578-e587.	4.7	29
11	Identifying counties at risk of high overdose mortality burden during the emerging fentanyl epidemic in the USA: a predictive statistical modelling study. Lancet Public Health, The, 2021, 6, e720-e728.	10.0	22
12	The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study. Lancet Public Health, The, 2019, 4, e127-e136.	10.0	21
13	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. Drug and Alcohol Dependence, 2020, 213, 108135.	3.2	20
14	Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. PLoS Medicine, 2019, 16, e1002973.	8.4	17
15	The Incidence Patterns Model to Estimate the Distribution of New HIV Infections in Sub-Saharan Africa: Development and Validation of a Mathematical Model. PLoS Medicine, 2016, 13, e1002121.	8.4	16
16	Integrating HIV preâ€exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. Journal of the International AIDS Society, 2020, 23, e25495.	3.0	14
17	Methodological approaches for the prediction of opioid use-related epidemics in the United States: a narrative review and cross-disciplinary call to action. Translational Research, 2021, 234, 88-113.	5.0	13
18	Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico. Journal of the International AIDS Society, 2020, 23, e25493.	3.0	11

Annick BÃ³rquez

#	Article	IF	CITATIONS
19	Modeling the populationâ€level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. Addiction, 2022, 117, 1338-1352.	3.3	11
20	Fatal overdose: Predicting to prevent. International Journal of Drug Policy, 2022, 104, 103677.	3.3	8
21	ls hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. International Journal of Drug Policy, 2021, 88, 102710.	3.3	7
22	Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers. AIDS and Behavior, 2021, 25, 3814-3827.	2.7	7
23	Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP): A systematic review and meta-analysis. International Journal of Drug Policy, 2021, 96, 103401.	3.3	5
24	Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research. Substance Use and Misuse, 2022, 57, 815-821.	1.4	5
25	Condom use by female sex workers and their clients in Mexico: who decides and does it matter?. Sexually Transmitted Infections, 2011, 87, 254-256.	1.9	4
26	Preferences and acceptability of law enforcement initiated referrals for people who inject drugs: a mixed methods analysis. Substance Abuse Treatment, Prevention, and Policy, 2020, 15, 75.	2.2	4
27	Impact of cumulative incarceration and the postâ€release period on syringeâ€sharing among people who inject drugs in Tijuana, Mexico: a longitudinal analysis. Addiction, 2021, 116, 2724-2733.	3.3	4
28	What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis. BMC Infectious Diseases, 2020, 20, 588.	2.9	2